11.23.20 | Research and Clinical Trials
SWHR Comments to FDA on MDUFA Reauthorization for Fiscal Years 2023-2027
The Society for Women’s Health Research (SWHR) submitted comments as a follow-up to the U.S. Food and Drug Administration (FDA) […]
10.2.20 | Research and Clinical Trials
Position Statement: Inclusion of Sex as a Biological Variable in Research
An Official Position Statement of the Society for Women’s Health Research POSITION Research must take into account sex as […]
9.9.20 | Research and Clinical Trials
SWHR Urges FDA OWH to Prioritize Inclusion of Pregnant Women in Clinical Trials
SWHR signed on to a comment letter from the Coalition to Advance Maternal Therapeutics (CAMT) regarding the inclusion of pregnant […]
9.8.20 | Research and Clinical Trials
SWHR Recommendations to FDA OWH on Strategic Priorities
SWHR submitted comments on the U.S. Food and Drug Administration (FDA) Office of Women’s Health’s strategic priorities. SWHR celebrates the […]
8.21.20 | Research and Clinical Trials
SWHR Recommendations to FDA for PDUFA Reauthorization for FY 2023-27
SWHR provided comments as a follow-up to the U.S. Food and Drug Administration (FDA) public meeting regarding the proposed recommendations […]
8.21.20 | Research and Clinical Trials
SWHR Feedback to NIH on Improving Biomedical Animal Research
SWHR provided comments to the National Institutes of Health (NIH) Advisory Committee to the Director Working Group on Enhancing Rigor, […]
7.30.20 | Uterine Fibroids
SWHR Applauds Uterine Fibroids Research and Education Act
SWHR President and CEO Kathryn Schubert, MPP, released the following statement in support of the Uterine Fibroids Research and Education […]
6.23.20 | Coronavirus
SWHR Feedback to Senate HELP Committee Chair on Pandemic Preparedness Plan
SWHR provided feedback on a white paper from Sen. Lamar Alexander, chair of the Senate Health, Education, Labor, and Pensions […]
6.19.20 | Coronavirus
SWHR Urges Inclusion of At-Risk Women in COVID-19 Research
SWHR joined 25 organizations in urging the Food and Drug Administration (FDA) and National Institutes of Health (NIH) to include […]
5.19.20 | Research and Clinical Trials
SWHR Comments on Cures 2.0 Legislation
SWHR provided Representative Diana DeGette (D-CO) and Representative Fred Upton (R-MI) with initial feedback today in response to their recent […]
